Immunovant (IMVT) said Monday it appointed director Eric Venker as chief executive, succeeding Pete Salzmann, who has retired.
The company also named Tiago Girao as chief financial officer, succeeding Renee Barnett, who has stepped down from the role. Girao previously served as CFO of Telavant.
Immunovant said the changes are part of a "strategic realignment" under which Roivant Sciences (ROIV) will lead all investor relations activity of the company.
The company said it is expanding the development of IMVT-1402 into two new indications, namely Sjogren's Disease and Cutaneous Lupus Erythematosus.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。